ESMO 2026 Preview: Oncology Innovations, Clinical Trials and AI
ESMO 2026 at a glance ESMO 2026 will spotlight emerging oncology trends as…
Oncology Strategic Roundup: Presicion Moves Earlier | Sep 11–Oct 15, 2026
Oncology market trends highlight growing competition around treatment…
Women's Health Strategic Roundup: Earlier Intervention | Sep 08 – Oct 13, 2026
Women’s health market trends signal a competitive shift toward earlier…
Merck–SciBrunch SPR2015: A $400M Preclinical Bet | Lucid Diligence Brief
This Lucid Diligence Brief examines Merck’s licensing deal for SciBrunch’s…
WCLC 2026 Preview: Emerging Lung Cancer Therapies and Competitive Trends
WCLC 2026 at a glance At IASLC-WCLC 2026, where will the next wave of…
Oncology Strategic Roundup | July 02 – Aug 07, 2026
Oncology Strategic Roundup exploring Developments and Competitive Shifts…
Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
Genprex and Roche Diagnostics begin TROP2 assay validation to support…
Nucleai-University of Glasgow Partnership Expands Spatial AI Platform | Lucid Diligence Brief
Nucleai broadened its University of Glasgow collaboration to expand academic…
Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
IDEAYA and Roche Collaboration | Lucid Diligence Brief
IDEAYA and Roche Test IDE892 plus RG6505 in MTAP-Deleted RAS-Mutant PDAC…
ASCO 2026: Competitive Shifts in Oncology
ASCO at a glance ASCO 2026 highlights how oncology innovation is being tested…
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay Raises SERENA-6…